Barinthus Biotherapeutics Future Growth
Future criteria checks 0/6
Barinthus Biotherapeutics's earnings are forecast to decline at 1.8% per annum while its annual revenue is expected to grow at 1.7% per year. EPS is expected to decline by 1.8% per annum.
Key information
-1.8%
Earnings growth rate
-1.8%
EPS growth rate
| Biotechs earnings growth | 26.7% |
| Revenue growth rate | 1.7% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 19 Nov 2024 |
Recent future growth updates
Recent updates
Barinthus Biotherapeutics plc (NASDAQ:BRNS) Surges 33% Yet Its Low P/S Is No Reason For Excitement
Jan 10
Barinthus Biotherapeutics plc (NASDAQ:BRNS) Not Doing Enough For Some Investors As Its Shares Slump 32%
Nov 19Is Barinthus Biotherapeutics (NASDAQ:BRNS) In A Good Position To Invest In Growth?
Aug 31Here's Why We're Watching Barinthus Biotherapeutics' (NASDAQ:BRNS) Cash Burn Situation
Apr 05We Think Vaccitech (NASDAQ:VACC) Can Afford To Drive Business Growth
Jul 07Vaccitech's (NASDAQ:VACC) Earnings Are Of Questionable Quality
Nov 17Vaccitech promotes Gemma Brown to CFO
Sep 20Analysts Just Made An Incredible Upgrade To Their Vaccitech plc (NASDAQ:VACC) Forecasts
Aug 15Vaccitech plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Aug 13Vaccitech GAAP EPS of $0.41, revenue of $17.06M
Aug 09Growth Investors: Industry Analysts Just Upgraded Their Vaccitech plc (NASDAQ:VACC) Revenue Forecasts By 51%
May 19Vaccitech: Aiming For A Cure In Chronic Hepatitis B
Apr 03Vaccitech: The Next Big Vaccine Trade
Jun 27Vaccitech EPS misses by $0.69, beats on revenue
Jun 14Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -72 | N/A | N/A | 2 |
| 12/31/2025 | N/A | -76 | N/A | N/A | 3 |
| 12/31/2024 | 10 | -66 | N/A | N/A | 3 |
| 9/30/2024 | 15 | -58 | -62 | -62 | N/A |
| 6/30/2024 | N/A | -64 | -55 | -55 | N/A |
| 3/31/2024 | 0 | -71 | -63 | -60 | N/A |
| 12/31/2023 | 1 | -73 | -56 | -51 | N/A |
| 9/30/2023 | 7 | -77 | -49 | -43 | N/A |
| 6/30/2023 | 13 | -55 | -28 | -20 | N/A |
| 3/31/2023 | 30 | -15 | -19 | -11 | N/A |
| 12/31/2022 | 45 | 5 | -21 | -14 | N/A |
| 9/30/2022 | 38 | 11 | -17 | -11 | N/A |
| 6/30/2022 | 32 | -1 | -29 | -25 | N/A |
| 3/31/2022 | 15 | -33 | -33 | -31 | N/A |
| 12/31/2021 | 0 | -51 | -34 | -33 | N/A |
| 9/30/2021 | 1 | -46 | -30 | -30 | N/A |
| 6/30/2021 | 4 | -41 | -29 | -28 | N/A |
| 3/31/2021 | 4 | -29 | -15 | -15 | N/A |
| 12/31/2020 | 5 | -18 | -11 | -11 | N/A |
| 12/31/2019 | 7 | -21 | -19 | -19 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BRNS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BRNS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BRNS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BRNS's revenue (1.7% per year) is forecast to grow slower than the US market (9% per year).
High Growth Revenue: BRNS's revenue (1.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BRNS's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 03:00 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Barinthus Biotherapeutics plc is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Yi Chen | H.C. Wainwright & Co. |
| Matthew Harrison | Morgan Stanley |